PDF(Pubmed)
Abstract：
UNASSIGNED: Our aim was to conduct a meta-analysis and systematic review in order to compare the diagnostic efficacy of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in patients with biochemically recurrent after radical prostatectomy and biochemically recurrent prostate cancers (BCR) after hybrid RT and RP.
UNASSIGNED: Up until February 2023, we searched PubMed, Embase, and Web of Science for pertinent papers. Studies examining the utility of 68Ga-PSMA-11 PET/CT or PET/MRI as a screening tool for biochemically recurrent prostate cancer were included. To measure heterogeneity, we employed the I2 statistic. In cases of substantial heterogeneity (I2 > 50%), we used the random effect model to produce a forest plot. In other cases, we utilized the fixed model. Furthermore, we assessed the quality of the studies included using the Quality Assessment of Diagnostic Performance Studies (QUADAS-2) method.
UNASSIGNED: In total, 37 studies involving 8409 patients were examined. For 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI, the combined total detection rate was 0.70 (95% CI: 0.65-0.75) and 0.71 (95% CI:0.67-0.75), respectively. 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI did not substantially differ in terms of the overall detection rate for BCR (P = 0.58). The detection rate was unaffected by the PSA values (all P > 0.05).
UNASSIGNED: The diagnostic efficacy of 68Ga-PSMA-11 PET/CT appears to be equivalent to that of 68Ga-PSMA-11 PET/MRI in detecting biochemically recurrent prostate cancer. Nonetheless, it should be noted that not all studies have used pathological biopsies as the gold standard. Therefore, additional larger prospective studies are needed to address this issue.
UNASSIGNED: identifier CRD42023410039.
UNASSIGNED: Up until February 2023, we searched PubMed, Embase, and Web of Science for pertinent papers. Studies examining the utility of 68Ga-PSMA-11 PET/CT or PET/MRI as a screening tool for biochemically recurrent prostate cancer were included. To measure heterogeneity, we employed the I2 statistic. In cases of substantial heterogeneity (I2 > 50%), we used the random effect model to produce a forest plot. In other cases, we utilized the fixed model. Furthermore, we assessed the quality of the studies included using the Quality Assessment of Diagnostic Performance Studies (QUADAS-2) method.
UNASSIGNED: In total, 37 studies involving 8409 patients were examined. For 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI, the combined total detection rate was 0.70 (95% CI: 0.65-0.75) and 0.71 (95% CI:0.67-0.75), respectively. 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI did not substantially differ in terms of the overall detection rate for BCR (P = 0.58). The detection rate was unaffected by the PSA values (all P > 0.05).
UNASSIGNED: The diagnostic efficacy of 68Ga-PSMA-11 PET/CT appears to be equivalent to that of 68Ga-PSMA-11 PET/MRI in detecting biochemically recurrent prostate cancer. Nonetheless, it should be noted that not all studies have used pathological biopsies as the gold standard. Therefore, additional larger prospective studies are needed to address this issue.
UNASSIGNED: identifier CRD42023410039.
摘要：
■我们的目的是进行荟萃分析和系统评价，以比较68Ga-PSMA-11PET/CT和68Ga-PSMA-11PET/MRI对前列腺癌根治术后生化复发和混合RT和RP后生化复发性前列腺癌（BCR）患者的诊断功效。
■直到2023年2月，我们搜索了PubMed，Embase,和WebofScience的相关论文。包括检查68Ga-PSMA-11PET/CT或PET/MRI作为生化复发性前列腺癌的筛查工具的实用性的研究。为了衡量异质性，我们采用了I2统计量。在实质性异质性(I2>50%)的情况下，我们使用随机效应模型来产生森林图。在其他情况下,我们使用了固定模型。此外，我们使用诊断性能研究质量评估(QUADAS-2)方法对纳入研究的质量进行评估.
■总共，检查了37项涉及8409名患者的研究。对于68Ga-PSMA-11PET/CT和68Ga-PSMA-11PET/MRI，合并总检出率为0.70（95％CI：0.65-0.75）和0.71（95％CI：0.67-0.75），分别。68Ga-PSMA-11PET/CT和68Ga-PSMA-11PET/MRI在BCR的总体检出率方面没有实质性差异(P=0.58)。检出率不受PSA值的影响(均P>0.05)。
■在检测生化复发性前列腺癌方面，68Ga-PSMA-11PET/CT的诊断功效似乎与68Ga-PSMA-11PET/MRI相当。尽管如此，值得注意的是,并非所有研究都将病理活检作为金标准.因此,需要更多更大规模的前瞻性研究来解决这一问题.
■标识符CRD42023410039。
■直到2023年2月，我们搜索了PubMed，Embase,和WebofScience的相关论文。包括检查68Ga-PSMA-11PET/CT或PET/MRI作为生化复发性前列腺癌的筛查工具的实用性的研究。为了衡量异质性，我们采用了I2统计量。在实质性异质性(I2>50%)的情况下，我们使用随机效应模型来产生森林图。在其他情况下,我们使用了固定模型。此外，我们使用诊断性能研究质量评估(QUADAS-2)方法对纳入研究的质量进行评估.
■总共，检查了37项涉及8409名患者的研究。对于68Ga-PSMA-11PET/CT和68Ga-PSMA-11PET/MRI，合并总检出率为0.70（95％CI：0.65-0.75）和0.71（95％CI：0.67-0.75），分别。68Ga-PSMA-11PET/CT和68Ga-PSMA-11PET/MRI在BCR的总体检出率方面没有实质性差异(P=0.58)。检出率不受PSA值的影响(均P>0.05)。
■在检测生化复发性前列腺癌方面，68Ga-PSMA-11PET/CT的诊断功效似乎与68Ga-PSMA-11PET/MRI相当。尽管如此，值得注意的是,并非所有研究都将病理活检作为金标准.因此,需要更多更大规模的前瞻性研究来解决这一问题.
■标识符CRD42023410039。
